Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment
Andrographolide is a plant-based compound that showed promising activity against lung cancer. However, the compound's poor water solubility and low bioavailability limit its oral administration. Inhaled drug delivery of andrographolide is highly favourable as it delivers active ingredients dire...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier Ltd
2024
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/111592/1/PIIS2405844024067926.pdf |
| _version_ | 1825940000714260480 |
|---|---|
| author | Masarudin, Mas Jaffri Jothi. N, Arul Mohtar, Noratiqah Parumasivam, Thaigarajan |
| author_facet | Masarudin, Mas Jaffri Jothi. N, Arul Mohtar, Noratiqah Parumasivam, Thaigarajan |
| author_sort | Masarudin, Mas Jaffri |
| collection | UPM |
| description | Andrographolide is a plant-based compound that showed promising activity against lung cancer. However, the compound's poor water solubility and low bioavailability limit its oral administration. Inhaled drug delivery of andrographolide is highly favourable as it delivers active ingredients directly into the affected lungs. In the current study, we compared in vitro aerosol performance, anti-cancer activity and storages stability of two (2) inhalable andrographolide formulations. Formulation 1 was prepared using precipitation and spray drying techniques, while Formulation 2 was prepared via direct spray drying technique. Drug morphology and physicochemical properties were confirmed using scanning electron microscopy (SEM) and X-ray diffraction (XRD) analysis. In vitro aerosol dispersion profile was evaluated using the next-generation impactor (NGI). Formulation 1 consisted of elongated crystals while Formulation 2 was made up of amorphous spherical particles. Both formulations had an inhalable fraction (<5 μm) of more than 40 %, making them suitable for pulmonary drug delivery. The formulations also showed an IC25 of less than 100 μg/mL against the human lung carcinoma cells (A549). Formulation 1 and 2 was stable in a vacuum condition at 30 °C for up to 6 and 3 months, respectively. Novel inhalable andrographolide dry powders were successfully produced with a good aerosol profile, potent anti-cancer activity and adequate storage stability, which deserve further in vivo investigations. |
| first_indexed | 2024-09-25T03:44:23Z |
| format | Article |
| id | upm.eprints-111592 |
| institution | Universiti Putra Malaysia |
| language | English |
| last_indexed | 2024-09-25T03:44:23Z |
| publishDate | 2024 |
| publisher | Elsevier Ltd |
| record_format | dspace |
| spelling | upm.eprints-1115922024-08-04T09:35:26Z http://psasir.upm.edu.my/id/eprint/111592/ Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment Masarudin, Mas Jaffri Jothi. N, Arul Mohtar, Noratiqah Parumasivam, Thaigarajan Andrographolide is a plant-based compound that showed promising activity against lung cancer. However, the compound's poor water solubility and low bioavailability limit its oral administration. Inhaled drug delivery of andrographolide is highly favourable as it delivers active ingredients directly into the affected lungs. In the current study, we compared in vitro aerosol performance, anti-cancer activity and storages stability of two (2) inhalable andrographolide formulations. Formulation 1 was prepared using precipitation and spray drying techniques, while Formulation 2 was prepared via direct spray drying technique. Drug morphology and physicochemical properties were confirmed using scanning electron microscopy (SEM) and X-ray diffraction (XRD) analysis. In vitro aerosol dispersion profile was evaluated using the next-generation impactor (NGI). Formulation 1 consisted of elongated crystals while Formulation 2 was made up of amorphous spherical particles. Both formulations had an inhalable fraction (<5 μm) of more than 40 %, making them suitable for pulmonary drug delivery. The formulations also showed an IC25 of less than 100 μg/mL against the human lung carcinoma cells (A549). Formulation 1 and 2 was stable in a vacuum condition at 30 °C for up to 6 and 3 months, respectively. Novel inhalable andrographolide dry powders were successfully produced with a good aerosol profile, potent anti-cancer activity and adequate storage stability, which deserve further in vivo investigations. Elsevier Ltd 2024-05-04 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/111592/1/PIIS2405844024067926.pdf Masarudin, Mas Jaffri and Jothi. N, Arul and Mohtar, Noratiqah and Parumasivam, Thaigarajan (2024) Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment. Heliyon, 10 (9). art. no. e30761. pp. 1-12. ISSN 2405-8440 https://www.sciencedirect.com/science/article/pii/S2405844024067926 10.1016/j.heliyon.2024.e30761 |
| spellingShingle | Masarudin, Mas Jaffri Jothi. N, Arul Mohtar, Noratiqah Parumasivam, Thaigarajan Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment |
| title | Novel inhaled andrographolide for treatment of lung cancer: in
vitro assessment |
| title_full | Novel inhaled andrographolide for treatment of lung cancer: in
vitro assessment |
| title_fullStr | Novel inhaled andrographolide for treatment of lung cancer: in
vitro assessment |
| title_full_unstemmed | Novel inhaled andrographolide for treatment of lung cancer: in
vitro assessment |
| title_short | Novel inhaled andrographolide for treatment of lung cancer: in
vitro assessment |
| title_sort | novel inhaled andrographolide for treatment of lung cancer in vitro assessment |
| url | http://psasir.upm.edu.my/id/eprint/111592/1/PIIS2405844024067926.pdf |
| work_keys_str_mv | AT masarudinmasjaffri novelinhaledandrographolidefortreatmentoflungcancerinvitroassessment AT jothinarul novelinhaledandrographolidefortreatmentoflungcancerinvitroassessment AT mohtarnoratiqah novelinhaledandrographolidefortreatmentoflungcancerinvitroassessment AT parumasivamthaigarajan novelinhaledandrographolidefortreatmentoflungcancerinvitroassessment |